Literature DB >> 26569060

Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.

Tine H Schnack1, Estrid Høgdall, Lotte Nedergaard, Claus Høgdall.   

Abstract

OBJECTIVE: To compare clinical demographic and prognostic factors as well as overall survival in a nationwide cohort of patients diagnosed with ovarian clear cell carcinoma (oCCC) and high grade ovarian serous adenocarcinoma (oSAC) during 2005 to 2013.
MATERIALS AND METHODS: Population-based prospectively collected data on oCCC (n = 179) and oSAC (n = 2363) cases were obtained from the Danish Gynecological Cancer Database. χ, Fischer or Wilcoxon-Mann-Whitney, multivariate logistic regression, univariate Kaplan-Meier, and multivariate Cox regression tests were used. Statistical tests were 2-sided. P values less than 0.05 were considered statistically significant.
RESULTS: The oCCC cases were significantly younger than oSAC cases. An inverse association between ever smoking and oCCC as compared to oSAC was observed and a significantly higher proportion of oCCC was found to be nulliparous (odds ratio, 0.62; 95% confidence interval, 0.37-0.92).Although more oSAC than oCCC cases diagnosed in stage III or IV were referred to neoadjuvant chemotherapy, a higher proportion of oCCC achieved complete cytoreduction at primary debulking surgery and/or had lymphadenectomy performed; overall survival were poorer among oCCC than oSAC cases in analyses restricted to stages III and IV (odds ratio, 1.87; 95% confidence interval, 1.35-2.61), whereas no difference between early stage oCCC and oSAC was observed.
CONCLUSIONS: The study confirms that demographic features and risk factors differ between oCCC and oSAC cases. Furthermore, our findings confirm that advanced stages of oCCC have a poorer prognosis compared with oSAC probably because of the resistance toward adjuvant chemotherapy. The observed differences highlight the need for subtype-specific research and individualized treatment within ovarian cancer.

Entities:  

Mesh:

Year:  2016        PMID: 26569060     DOI: 10.1097/IGC.0000000000000585

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

2.  Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?

Authors:  Jing Wang; Yuying Shi; Yan Liu; Wei Li; Hong Jiang; Hongbing Cai
Journal:  Cancer Manag Res       Date:  2020-11-13       Impact factor: 3.989

3.  Prognostic factors in epithelial ovarian cancer: A population-based study.

Authors:  Lin-Chau Chang; Chih-Fen Huang; Mei-Shu Lai; Li-Jiuan Shen; Fe-Lin Lin Wu; Wen-Fang Cheng
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

4.  Identification of potential key genes associated with ovarian clear cell carcinoma.

Authors:  Youzheng Xu; Keng Shen
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

5.  Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma.

Authors:  Shu-Feng Hsieh; Hei-Yu Lau; Hua-Hsi Wu; Heng-Cheng Hsu; Nae-Fang Twu; Wen-Fang Cheng
Journal:  Int J Environ Res Public Health       Date:  2019-02-21       Impact factor: 3.390

6.  The prevalence of EBV and CMV DNA in epithelial ovarian cancer.

Authors:  Kasper Ingerslev; Estrid Høgdall; Wojciech Skovrider-Ruminski; Tine Henrichsen Schnack; Marianne Lidang; Claus Høgdall; Jan Blaakaer
Journal:  Infect Agent Cancer       Date:  2019-02-26       Impact factor: 2.965

7.  Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer.

Authors:  Abolfazl Khalafi-Nezhad; Vahid Ebrahimi; Fatemeh Ahmadpour; Mozhdeh Momtahan; Minoo Robati; Zahra Saraf; Mani Ramzi; Zahra Jowkar; Parvin Ghaffari
Journal:  Cancer Manag Res       Date:  2020-02-26       Impact factor: 3.989

8.  Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.

Authors:  Jun Zhu; Hao Wen; Rui Bi; Yong Wu; Xiaohua Wu
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

9.  Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.

Authors:  Young Shin Chung; Jung Yun Lee; Hyun Soo Kim; Eun Ji Nam; Sang Wun Kim; Young Tae Kim
Journal:  Yonsei Med J       Date:  2018-10       Impact factor: 2.759

10.  Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution.

Authors:  Yuying Shi; Mengyuan Dai; Yaxing Zhang; Yuwen Qi; Zhen Li; Hongbing Cai
Journal:  Cancer Manag Res       Date:  2021-03-04       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.